Detecting TERT mutations is crucial for diagnosis and treatment planning. Techniques such as next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based methods are commonly used. These techniques allow for the identification of specific mutations in the TERT promoter region, enabling personalized treatment approaches. Liquid biopsy is an emerging technique that holds promise for non-invasive detection of TERT mutations, particularly in monitoring disease progression and response to therapy.
